• The company’s lead candidate, OT-101, is currently in a Phase 3 trial for pancreatic cancer and is advancing toward combination studies with checkpoint inhibitors.
• A joint venture with GMP Biotechnology enables Oncotelic to conduct low-cost research and development, operate in-house GMP manufacturing, and support a rapidly expanding nanoparticle pipeline trademarked Deciparticle(TM).
• A strategic partnership with Shanghai Medicilon supports rapid IND filings for up to 20 drug candidates, significantly accelerating development timelines.
• Oncotelic’s proprietary AI platform, PDAOAI, enhances regulatory and research workflows while offering public engagement tools for added transparency.
• The company maintains a multi-indication pipeline spanning oncology, Parkinson’s disease, erectile dysfunction and female sexual Dysfunction, providing broad commercialization potentials.
• Recent peer-reviewed publications support OT-101’s mechanism of action and spotlight TGF-β2 as a survival-linked biomarker in younger PDAC patients.

Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy, and targeted therapeutics for cancer and other underserved diseases. The company is focused on transforming outcomes for patients with difficult-to-treat and rare conditions, particularly pediatric cancers and aggressive solid tumors. Its development strategy centers on novel compound design, nanoparticle drug delivery, and the integration of artificial intelligence to accelerate discovery and regulatory workflows.

At the center of this foundation is Chairman and CEO Dr. Vuong Trieu, a prolific industry pioneer who has filed more than 500 patents with 75 issued patents across biologics, small molecules, nanoparticles, and diagnostics. Dr. Trieu co-invented Abraxane® (sold to Celgene for $2.9 billion), underscoring his track record of creating high-value therapies. Through collaborations with industry leaders and its stake in specialized joint ventures, Oncotelic is positioned to advance a diverse portfolio of oncology assets with greater speed and cost efficiency. The company also operates a proprietary AI platform, PDAOAI, which streamlines scientific writing, regulatory documentation, and data interpretation. This system is accessible to the public through a dedicated Discord server, offering real-time engagement with Oncotelic’s research ecosystem.

With expanded clinical activity and a next-generation development model, Oncotelic continues to evolve as a multi-asset innovator in precision oncology.

The company is headquartered in Agoura Hills, California.

Pipeline and Partnerships

Oncotelic’s lead candidate is OT-101, currently in a Phase 3 trial for pancreatic ductal adenocarcinoma (STOP-PC study) and evaluated in gliomas and metastatic solid tumors in combination with IL-2 and checkpoint inhibitors. The antisense molecule targets TGF-β2, a cytokine known to suppress immune responses and promote tumor growth. A Phase 1 trial combining OT-101 with IL-2 was recently completed, demonstrating safety and paving the way for combination therapies with PD-1 blockers and other immunotherapies.

Recent data have further strengthened the rationale for OT-101 in pancreatic ductal adenocarcinoma (“PDAC”). In June and July 2025, two peer-reviewed studies published in the International Journal of Molecular Sciences identified TGF-β2 gene expression and methylation status as significant prognostic markers in PDAC, particularly among younger patients and those with low CD8+ T-cell infiltration. High TGF-β2 expression correlated with reduced overall survival, while elevated TGF-β2 methylation was associated with improved outcomes. These findings validate TGF-β2 as a high-priority target and support the continued development of OT-101 as a precision therapy. Both studies leveraged Oncotelic’s proprietary AI-driven platform, PDAOAI, to mine and assemble multi-omic datasets, showcasing the system’s role in accelerating insight generation.

The company holds a 45% ownership stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited. GMP Bio owns SAPU Bioscience, which is executing several pipeline programs. SAPU and Oncotelic are jointly utilizing a rapid IND platform through their partnership with Shanghai Medicilon to support regulatory filings for up to 20 drug candidates, with five INDs already underway. This collaboration is central to accelerating development of next-generation anticancer agents.

After the joint venture, Dr. Trieu, with his team, built out a state of the art and GMP-certified R&D facility in San Diego, which operates under SAPU, that manufactures clinical trial materials and supports a proprietary nanoparticle platform trademarked Deciparticle(TM). This platform includes four therapeutic candidates—two of which are in late-stage manufacturing and expected to enter IND filing before the end of 2025.

Additionally, Oncotelic owns AL-101, an intranasal administered apomorphine product intended for the treatment of Parkinson’s disease, Erectile Dysfunction, and Female Sexual Disorders.

Market Opportunity

Oncotelic is targeting large and underserved therapeutic markets with significant commercial potentials. The global pancreatic cancer treatment market alone is projected to grow at a 12.3% CAGR, reaching $5.84 billion by 2030, up from $2.92 billion in 2024, according to Research and Markets. This growth is driven by increased disease prevalence, aging populations, and demand for more effective treatment options. Notably, the incidence of early-onset PDAC is rising at an estimated rate of 4% per year in the 15–34 age group, highlighting an emerging unmet need for targeted therapies among younger patients.

Beyond oncology, Oncotelic intends to develop AL-101 for Parkinson’s disease, which affects over 1 million patients in the U.S. alone and is expected to impact 1.2 million by 2030. Erectile Dysfunction and Female Sexual Dysfunction are also major global health issues, with Erectile Dysfunction affecting up to 70% of men over 60 and Female Sexual Dysfunction impacting approximately 40% of women—both with limited treatment options, particularly for patients who fail to respond to existing medications. These underserved populations offer fertile ground for innovative new therapies.

Leadership Team

Dr. Vuong Trieu is the Chairman and CEO of Oncotelic Inc. An accomplished innovator in pharmaceutical development, Dr. Trieu previously served as President and CEO of Igdrasol, where he pioneered the approval path for paclitaxel nanomedicine via a single bioequivalence trial. After Igdrasol merged with Sorrento Therapeutics, he became Chief Scientific Officer and a Board Director. He also held leadership roles at Cenomed, Abraxis, Applied Molecular Evolution, and Parker Hughes Institute. Dr. Trieu holds a Ph.D. in Molecular Microbiology, a B.S. in Botany, has published widely, and filed over 500 patent applications with 75 issued U.S. patents.

Amit Shah is the Chief Financial Officer of Oncotelic Inc. He has over 20 years of financial leadership in life sciences, including CFO roles at Marina Biotech and Igdrasol, and senior positions at ISTA Pharmaceuticals, Spectrum Pharmaceuticals, and Caraco. He also worked in consulting and ERP implementation. Mr. Shah holds a Bachelor of Commerce from the University of Mumbai, is an Associate Chartered Accountant in India, and is an inactive CPA in Colorado.

Dr. Anthony E. Maida III is the Chief Clinical Officer – Translational Medicine at Oncotelic Inc. He has over 25 years of experience advancing cancer immunotherapies and held senior roles at Northwest Biotherapeutics, PharmaNet, and Jenner Biotherapies. He has raised over $200 million for biotech firms and negotiated licensing deals with institutions such as Pfizer, Eli Lilly, and Yale. Dr. Maida holds dual B.A. degrees in Biology and History, an MBA, an M.A. in Toxicology, and a Ph.D. in Immunology, and is active in ASCO, AACR, and other scientific societies.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

Global demand for energy is picking up, in part due to rising power demand fueled by new technologies like AI and EVs. Now, investors can learn new ways to profit at the MoneyShow Virtual Expo, scheduled for Sept. 9-10, 2025. Attendees at the online event will get tips and recommendations across the natural gas, crude oil, and alternative energy sectors.

Participants can also engage with eminent industry veterans to learn novel ways and tools to protect and grow their wealth. MoneyShow Virtual Expos are designed to provide investors and traders with powerful market opportunities and resources to maximize returns. The company has been planning and hosting live and online events for 44 years, providing businesses, exhibitors, and investors with expert advice, resources, and marketing and networking opportunities.

At this MoneyShow bootcamp, experts will share insights and details on both public and private energy sector profit and income opportunities. Dozens of real-time LIVE presentations will also offer current market analysis and actionable takeaways.

The MoneyShow Virtual Expo will also feature virtual booths with message boards, research, videos on investments and trading, and prizes. New and seasoned players can pitch their products and services to gain visibility among traders, investors, and industry experts, while attendees can ask questions of the experts in a highly interactive event format.

Plus, exhibitors can connect with investors in one-on-one Zoom meetings to present their business ideas and plans. Attendees will also have access to a collection of downloadable educational content that they can store in a digital briefcase.

Registrations are open. To know more, please visit https://ibn.fm/qKNBN.

• BreastCT.com launches as a comprehensive educational resource focused on dedicated breast CT technology and IzoView’s clinical advantages for dense breast tissue imaging
• Platform designed to evolve alongside company progression through clinical studies, regulatory phases, and commercial launch milestones
• Strategic positioning within successful imaging category creation context provides clear market reference framework for IzoView’s commercial potential

The Pre-Commercial Challenge: Educating Markets on Breakthrough Technology

Medical device companies developing breakthrough technologies face a fundamental commercialization challenge beyond regulatory approval: market education. When innovations represent genuine advances over existing standards of care, successful adoption requires comprehensive stakeholder education across patients, clinicians, and healthcare administrators.

Izotropic (CSE: IZO) (OTCQB: IZOZF) launched BreastCT.com as a strategic response to this market education requirement, creating a dedicated platform to support awareness initiatives for breast CT technology and the company’s IzoView Breast CT Imaging System.

BreastCT.com focuses specifically on dedicated breast CT technology’s potential to address persistent challenges in detecting breast cancer with dense breast tissue, representing approximately 50% of screening populations. Dense breast tissue creates fundamental imaging challenges for conventional mammography, where overlapping structures can mask cancer and reduce diagnostic confidence.

This limitation affects screening effectiveness for millions of women while creating downstream costs through additional imaging, callbacks, and unnecessary interventions driven by inconclusive results. The educational platform positions IzoView’s capabilities within this clinical context, explaining how dedicated breast CT technology can provide enhanced visualization without compression-related limitations that constrain conventional imaging approaches.

With IzoView’s engineering phase complete, the website serves as a central resource for information about the technology’s clinical advantages and potential applications.

Dynamic Content Strategy Aligns with Development Milestones

Rather than static information delivery, BreastCT.com is designed to evolve alongside Izotropic’s progression through clinical study preparation, regulatory phases, and commercialization activities. This dynamic approach ensures content remains relevant and timely as the company advances through different development stages.

The platform will integrate updates on clinical study design, regulatory milestones, and commercialization planning while maintaining focus on educating audiences about breast CT technology’s clinical advantages. At strategic intervals, Izotropic plans to integrate native advertising campaigns within BreastCT.com to amplify awareness initiatives in alignment with corporate objectives.

Market Context Provides Commercial Framework

BreastCT.com positions Izotropic within broader industry context by highlighting public companies that successfully created and led new imaging categories. This comparative framework gives audiences clear reference points for understanding where breast CT technology could fit within evolving medical imaging markets.

This positioning strategy addresses a common challenge for breakthrough medical technologies: helping stakeholders understand market potential by referencing successful precedents in adjacent categories. The market context demonstrates Izotropic’s sophisticated understanding of commercialization requirements beyond technical development.

Building Recognition Ahead of Clinical Milestones

The BreastCT.com launch occurs as Izotropic prepares for clinical study initiation and regulatory submission activities. This timing enables the company to build stakeholder awareness and market understanding before pivotal clinical data becomes available, creating educated audiences prepared to evaluate study results within appropriate clinical contexts.

Market education platforms prove particularly valuable for companies developing first-in-category technologies, where stakeholders need foundational understanding of new approaches before evaluating specific clinical evidence. The platform supports Izotropic’s broader awareness initiatives, including podcast series and investor outreach activities derived from the company’s comprehensive strategic business plan.

Strategic Foundation for Commercial Success

BreastCT.com represents more than marketing infrastructure; it demonstrates Izotropic’s comprehensive approach to commercialization planning that integrates market education with clinical development and regulatory strategy. Companies that successfully commercialize breakthrough medical technologies typically begin market preparation years before regulatory approval, creating stakeholder awareness that accelerates post-approval adoption.

The educational platform positions Izotropic to capitalize on growing recognition of dense breast imaging challenges while building understanding of how dedicated CT technology can address current screening limitations. The strategic timing of the platform launch, coordinated with IzoView’s engineering completion and clinical study preparation, demonstrates sophisticated commercialization planning.

For more information, visit the company’s website at www.IzoCorp.com

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

• WLDS’s newly granted U.S. patent protects groundbreaking neural interface technology that measures weight, torque, and force directly from wrist-based sensors with applications spanning XR, industrial automation, and assistive technology
• The patent encompasses voice-controlled interfaces and innovations in brain-computer interfaces, strengthening the company’s intellectual property position in the rapidly expanding $260 billion AI wearables market
• Patent protection covers real-world physical measurement capabilities that differentiate WLDS from gesture-only competitors, opening industrial and manufacturing applications beyond consumer electronics

The neural interface revolution is unfolding differently than most technological observers anticipated. While industry attention focused on brain-computer interfaces requiring surgical implants or complex headsets, the real breakthrough is happening at the wrist. Companies are discovering that sophisticated neural signal processing can decode human intent through subtle muscle movements and bioelectric patterns, creating seamless control interfaces that require no learning curve or behavioral adaptation.

This shift represents more than incremental improvement in wearable technology. Traditional gesture control systems rely on visible movements detected by cameras or accelerometers, limiting their utility in professional environments where discrete, precise control is essential. Neural interface technology transcends these limitations by reading EMG signals directly from the wrist, enabling control through imperceptible finger movements and thought-initiated muscle activations.

The commercial implications extend far beyond consumer electronics into industrial automation, medical devices, and assistive technology markets where hands-free operation isn’t convenience, it’s necessity. What distinguishes the current technology wave is the convergence of miniaturized sensors, advanced signal processing algorithms, and artificial intelligence capabilities that enable real-time interpretation of complex neural patterns. Companies that secure intellectual property protection for core neural interface technologies are positioning themselves to capture value across multiple high-growth sectors as these applications scale.

That strategic positioning defines Wearable Devices (NASDAQ: WLDS), a neural interface pioneer that recently secured critical U.S. patent protection for technologies that could redefine human-machine interaction across industries.

Patent Protection Validates Core Technology

WLDS’s newly granted patent titled “Gesture and Voice-Controlled Interface Device” represents significant advancement in neural interface intellectual property. Unlike typical gesture patents focused on movement recognition, this protection covers neural measurement of physical forces: weight estimation, torque measurement for rotating objects, and applied force quantification for precise assembly tasks.

These capabilities transform neural interfaces from entertainment accessories into industrial tools. The patent protects technology that can measure torque when fastening screws, estimate object weight during lifting operations, and quantify connector seating force in cable harness assembly. Such applications address real operational challenges in manufacturing, logistics, and maintenance environments where precise force feedback improves quality and safety.

This measurement precision stems from WLDS’s proprietary approach to neural signal interpretation. Expanding beyond detecting gesture intentions, the technology analyzes muscle activation patterns that correspond to specific physical forces. This enables quantitative feedback that traditional gesture systems cannot provide, creating applications in sectors demanding measurable performance criteria.

Guy Wagner, co-founder and Chief Scientific Officer, emphasized the patent’s strategic importance: “We’re excited to integrate these advanced neural capabilities into our product lines and demonstrate their transformative potential in real-world environments.” This statement signals WLDS’s intention to commercialize beyond consumer applications into industrial markets where neural interface precision creates measurable operational value.

The patent also encompasses voice command integration and extended reality embodiment, protecting WLDS’s comprehensive approach to multimodal neural interfaces. This prevents competitors from circumventing patent protection through alternative input combinations while positioning WLDS to capture value from diverse application scenarios.

Industrial Applications Drive Market Expansion

WLDS’s patent portfolio addresses three distinct market opportunities that leverage neural interface technology differently. Extended reality applications benefit from immersive interaction capabilities that enhance user embodiment without visible gestures that break presence. Industrial and manufacturing environments gain precision measurement tools that improve quality control and worker safety through real-time force feedback.

Manufacturing applications offer immediate commercial opportunities. Assembly line workers performing repetitive tasks benefit from neural feedback that ensures consistent torque application and connection integrity. Quality control processes gain real-time measurement capabilities that detect assembly errors before they propagate downstream.

These applications distinguish WLDS from competitors focused exclusively on consumer gesture control. While entertainment and lifestyle applications drive initial market adoption, industrial use cases provide sustainable competitive advantages through higher switching costs and deeper integration requirements.

Strategic IP Development Supports Growth

WLDS’s patent strategy reflects sophisticated understanding of neural interface commercialization challenges. Rather than pursuing narrow protection for specific implementations, the company secured broad coverage for fundamental measurement capabilities that enable multiple product configurations and application scenarios.

This approach creates both a defensive patent moat and offensive positioning, while preserving commercial flexibility. As neural interface applications expand across industries, WLDS can adapt its technology platform to serve diverse market requirements without requiring fundamental architectural changes. Patent protection ensures competitors cannot replicate core measurement capabilities that differentiate WLDS solutions.

The company’s emphasis on building “a broad and adaptable global patent portfolio covering future applications of wearable bio-potential sensors” indicates systematic IP development aligned with long-term market expansion. This strategic framework positions WLDS to capture value from neural interface adoption across consumer, industrial, and medical markets.

Market Positioning and Commercial Potential

The AI wearables market’s projected growth from $21.2 billion in 2022 to $166.5 billion by 2030 creates substantial opportunities for companies with differentiated neural interface technologies. Neural inputs are the missing link to make AI assistance truly hands-free across platforms, whether on Android devices, iOS ecosystems, or future wearable operating systems, creating a universal interaction layer that device makers cannot ignore.  WLDS’s patent-protected measurement capabilities position the company to serve industrial and medical markets that demand higher precision and reliability than consumer applications.

Neural interface technology adoption follows predictable patterns: early consumer adoption validates core functionality, industrial applications provide sustainable revenue streams, and medical markets offer the highest value opportunities. WLDS’s comprehensive patent protection enables participation across all three market segments while competitors remain limited to specific application areas. While building its patents portfolio, the company is also adapting knowledge from new advances in neuroscience to meet emerging market needs in interfaces to digital devices, AI, and industrial solutions.

The company’s positioning at the intersection of neural sensing, artificial intelligence, and industrial automation aligns with broader technological convergence trends. As manufacturing systems become increasingly automated and responsive, neural interfaces provide natural human-machine communication channels that complement rather than replace existing control systems.

For more information, visit www.WearableDevices.co.il.

NOTE TO INVESTORS: The latest news and updates relating to WLDS are available in the company’s newsroom at https://ibn.fm/WLDS

• Trilogy Metals is boldly advancing one of North America’s most promising mineral districts: the Ambler Mining District in Alaska
• TMQ is a significant player in one of the richest and most prospective copper-dominant areas globally
• The company continues to advance its projects with a focus on sustainable development, community engagement and environmental responsibility

With a focus on high-grade copper, zinc, lead, gold and silver, Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) is not only exploring and developing critical metal resources but also championing responsible, sustainable mining practices that balance economic growth with environmental stewardship. The company is boldly advancing one of North America’s most promising mineral districts: the Ambler Mining District in Alaska. Trilogy Metals’ work in this remote and resource-rich region positions it at the forefront of providing essential metals that power the transition to a cleaner, greener global economy (ibn.fm/mZGnT).

Trilogy Metals’ mission is to develop the Ambler Mining District in a safe and environmentally responsible manner while respecting and protecting the culture and way of life of the local indigenous people. The company adheres to core values of safety, community, communication, teamwork, respect and integrity, engaging with stakeholders transparently and honestly (ibn.fm/nKE6Y).

Trilogy’s primary assets are located within the Upper Kobuk Mineral Projects (“UKMP”), encompassing approximately 471,796 acres in northwest Alaska. These projects include the Arctic and Bornite deposits, which are among the most developmentally advanced in the region. The Arctic deposit is a volcanogenic massive sulphide (“VMS”) deposit containing copper, zinc, lead, gold and silver, while the Bornite deposit is a carbonate replacement deposit hosting high-grade copper and cobalt mineralization.

Trilogy Metals holds a 50% interest in Ambler Metals LLC, a joint venture with South32 Limited, a globally diversified mining company (ibn.fm/nV9J2). Ambler Metals owns 100% of the UKMP, positioning Trilogy Metals as a significant player in one of the richest and most prospective copper-dominant areas globally.

A critical component of the company’s development strategy is the Ambler Access Project, which aims to construct a 211-mile industrial access road from the Dalton Highway to the Ambler Mining District (ibn.fm/iZWbv). This road is essential for transporting ore and facilitating mine development. The project is a collaborative effort involving the Alaska Industrial Development, Export Authority (“AIDEA”) and local communities.

Trilogy Metals continues to advance its projects with a focus on sustainable development, community engagement, and environmental responsibility. The company’s efforts in the Ambler Mining District are poised to play a significant role in meeting the growing global demand for essential metals needed for electrification, advanced technologies and infrastructure development.

For more information, visit www.TrilogyMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMQ are available in the company’s newsroom at ibn.fm/TMQ

• SuperCom secures a second electronic monitoring (“EM”) contract in Alabama, strengthening its foothold in the state.
• The company has entered 11 new U.S. states since mid-2024, including Tennessee in July.
• Contracts follow a recurring revenue model, with agencies billed per daily active unit.
• Referrals from existing clients have driven repeat contracts, highlighting customer satisfaction.
• SuperCom’s PureSecurity(TM) Suite supports GPS monitoring, house arrest, and domestic violence prevention programs.
• Rising adoption of EM solutions reflects demand for alternatives to incarceration and data-driven public safety management.

SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, is accelerating its push into the U.S. corrections market. The company announced a second contract in Alabama last week, extending its operations in a state it only entered earlier this year. The news follows last month’s agreement in Tennessee, which marked SuperCom’s expansion into its 11th new U.S. state in less than a year.

The new Alabama contract was awarded directly by a community corrections agency and is structured under a recurring revenue model based on daily active monitoring units (https://ibn.fm/NAekG). It will deploy the company’s PureSecurity(TM) Suite, anchored by the PureOne(TM) GPS tracking bracelet. According to SuperCom, the award came via referral from an existing customer in the region, underscoring a strategy of building out its U.S. presence through performance-based recommendations.

Chief Executive Ordan Trabelsi said the second Alabama win validates the company’s approach. “Securing a second win in Alabama within a short timeframe validates the strength of our technology, the satisfaction of our existing customers, and the growing network effect we’re seeing in states where we operate,” said Trabelsi. “Being recommended by a current client is one of the strongest validations of our work—and it’s a pattern we’ve seen in California, West Virginia, Kentucky, and beyond, where early wins have translated into sustained regional growth.”

The Alabama development comes only weeks after SuperCom entered Tennessee through a partnership with an established electronic monitoring provider in the state (https://ibn.fm/grMoN). That deal includes the rollout of both PureOne and PureShield, a system designed to prevent domestic violence. SuperCom reported that the Tennessee provider chose to transition away from legacy systems after evaluating multiple technology vendors, citing SuperCom’s tracking precision and integration capabilities as key factors.

The Tennessee engagement follows a similar recurring revenue model, billing monthly based on the number of units deployed. For SuperCom, these contracts create a predictable revenue stream while offering upside as agencies scale up programs.

SuperCom’s PureSecurity platform combines GPS, RFID, and cloud-based monitoring capabilities. The technology supports a range of programs, including offender tracking, probation monitoring, and domestic violence prevention.

Key components include:

• PureOne(TM): a one-piece GPS tracking bracelet.
• PureShield(TM): a system enforcing court-mandated movement restrictions, often deployed in domestic violence cases.
• PureProtect(TM): a smartphone application for victims that alerts them to proximity violations.
• PureMonitor(TM): a monitoring software platform for real-time supervision.

The modular design allows agencies to tailor monitoring approaches to their specific legal and operational frameworks.

Adoption of electronic monitoring is growing globally as governments search for alternatives to incarceration that are both cost-effective and effective in reducing re-offending. Research suggests EM can deliver meaningful improvements. Studies in Argentina, Australia, and France have reported reductions in recidivism ranging from 10% to nearly 50%, depending on the program design and population studied.

These findings support EM’s potential role in balancing public safety objectives with rehabilitation and resource management. For jurisdictions with overcrowded prisons and limited budgets, EM provides a flexible tool for managing offenders in the community.

SuperCom’s U.S. expansion is being underpinned by strong financials. “This milestone further reinforces our successful U.S. expansion strategy. Since mid-2024, we’ve secured over 30 new contracts, entered 11 new states, and displaced multiple incumbent vendors,” Trabelsi added. “Our momentum is supported by strong financial results, including record first-half net income of $5.3 million and 61.2% gross margin. As we continue to expand our presence and help agencies enhance public safety, we remain committed to disciplined execution and customer success,” Trabelsi concluded. “Each successful rollout solidifies our position as a trusted public safety partner and drives our global strategy forward.”

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at https://ibn.fm/SPCB

• The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million Americans who consider suicide annually.
• Clinical trials demonstrated rapid and statistically significant reductions in suicidal ideation with IV ketamine versus placebo and comparators.
• Fast Track status makes NRX-100 eligible for Accelerated Approval and the Commissioner’s National Priority Voucher program.
• NRx is preparing an expanded access policy and seeking meetings with FDA leadership to align on data submission.
• The U.S. suicidal depression market is estimated at more than $3 billion annually.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its intravenous ketamine formulation, NRX-100, for the treatment of suicidal ideation in patients with depression, including bipolar depression (https://ibn.fm/LYPf7).

The new designation expands NRX-100’s potential patient population by tenfold compared to the FDA’s 2017 designation, which was limited to use in combination with NRX-101 for suicidal bipolar depression. This expansion also reflects the FDA’s determination that NRX-100 has the potential to address an “unmet medical need.” That determination is a prerequisite for eligibility under the Commissioner’s National Priority Voucher (“CNPV”) program, which could shorten the review timeline.

The broader indication covers an estimated 13 million Americans who experience suicidal ideation annually, with 1.5 million attempts and one death every 11 minutes, according to Centers for Disease Control data. Treatment options remain limited, particularly for patients experiencing acute suicidal ideation (https://ibn.fm/xrF6G).

Several controlled trials informed the FDA’s decision. A Columbia University study licensed by NRx showed that IV ketamine achieved a 55% response rate, defined as a 50% reduction in suicidality, compared to 30% in patients receiving an active comparator. The results were statistically significant (P<.02).

Similarly, a French government-sponsored trial found that 63% of patients achieved full remission from suicidal ideation within three days of IV ketamine administration, compared to 31% for placebo (P<.001).

These outcomes have not been replicated with intranasal ketamine, which is sometimes used off-label for depression.

Fast Track designation enables closer interaction with the FDA, rolling review of new drug application materials, and potential eligibility for accelerated approval. NRx Pharmaceuticals has applied for the CNPV program and intends to meet with FDA leadership to finalize data submission plans.

The company also announced it will publish an expanded access policy within two weeks, a step that could allow certain patients earlier access to the drug while trials continue.

NRx Pharmaceuticals estimates that NRX-100 could target a U.S. suicidal depression market valued at more than $3 billion annually. Importantly, while ketamine is widely used off-label for mood disorders, FDA approval would make reimbursement by most insurers more likely, broadening patient access beyond those who can pay out of pocket.

NRX-100 is also notable as the first preservative-free IV ketamine formulation submitted to the FDA. Existing products often include benzethonium chloride (“BZT”), a preservative not recognized as safe by regulators. NRx’s formulation demonstrated long-term stability and sterility, with an anticipated three-year room temperature shelf life.

The company recently filed a Citizen Petition requesting that BZT-containing products be removed from the market and has initiated U.S.-based high-volume manufacturing for its preservative-free version.

Dr. Jonathan Javitt, Chairman and CEO of NRx, described the Fast Track designation as “a significant step forward” in the company’s mission to address the suicide crisis among both civilian and military populations. “Large-scale government-supported trials have demonstrated a robust and statistically significant reduction in suicidal ideation and depression with administration of ketamine,” Dr. Javitt added. “This drug was also proven to be non-inferior to electroshock therapy in treating depression without the negative side effects of ECT. We look forward to working closely with the FDA in our quest to Bring Hope to Life.”

For more information, visit the company’s website at www.NRxPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

• AI is transforming performance marketing by enabling personalized strategies and empowering marketers with data insights
• ONAR Holding Corp. has embraced this AI-driven evolution with inventive tools and strategic collaborations designed to enhance marketing effectiveness
• CEO Zdanow frames ONAR as a hybrid model combining strategic services, AI insights and scalable execution to empower companies to grow faster and smarter

Artificial intelligence (“AI”) is rewriting the rules of modern marketing, unlocking new ways to connect with consumers through personalization, automation, and data-driven insights. ONAR Holding Corp. (OTCQB: ONAR) is positioning itself at the center of this transformation, harnessing AI through proprietary technology and strategic partnerships to help brands achieve smarter, faster and more impactful growth.

MarTech recently reported on how AI is transforming conveniency in performance marketing by fueling rapid content creation, ultimately dampening marketers’ power to engage (ibn.fm/69MmA). ONAR actively challenges that notion with its key proprietary technology and data insights to deliver detailed ad targeting and predictive analytics, maximizing the impact of a client’s advertising spend. The report emphasized the critical role of strategic thinking among AI assistants, but unlike generic AI tools that produce surface-level outputs, ONAR’s services are designed to elevate this blueprint and demonstrate how technology can reinforce a marketing strategy.

ONAR has embraced this AI-driven evolution with inventive tools and strategic collaborations designed to enhance marketing effectiveness. Through ONAR Labs, the company created Cortex, a proprietary AI marketing intelligence platform that consolidates performance data across channels, forecasts trends, models attribution, and enables cross-platform integration (ibn.fm/MIoCZ). Cortex has powered substantial agency-driven client growth, contributing to more than $200 million in cumulative revenue across ONAR’s network of agency brands.

Expanding on this foundation, ONAR recently announced a multiagentic infrastructure in partnership with IQSTEL and its AI arm, Reality Border (ibn.fm/1uW0V). This scalable AI ecosystem deploys interconnected AI agents (“AIRWEB” agents) to automate tasks, enhance creative strategy and deliver real-time campaign intelligence, without compromising data security or creative oversight. This phased rollout, which includes streamlining, strategic enablement and creative augmentation, reflects ONAR’s commitment to accelerating client performance through AI-enhanced workflows.

Such initiatives place ONAR at the forefront of AI-led marketing innovation. The company’s strategic orientation is further attested by statements from CEO Claude Zdanow and multiple industry profiles (ibn.fm/R7TWo). Zdanow frames ONAR as more than a traditional agency or platform; instead, it is a hybrid model combining strategic services, AI insights and scalable execution to empower middle-market companies to grow faster and smarter. He emphasizes that brands at this stage need solutions that are agile and creative, yet backed by data, and ONAR provides exactly that.

Together, ONAR’s internal innovations and external partnerships illustrate how AI can transform marketing from a reactive tactic into a forward-looking catalyst for business performance, particularly when married with smart data architecture, creative insight and operational security. By embedding AI throughout its systems, ONAR ensures that campaigns are not just faster but more thoughtful, measurable and aligned with revenue outcomes.

For more information, visit the company’s website at www.ONAR.com.

NOTE TO INVESTORS: The latest news and updates relating to ONAR are available in the company’s newsroom at https://ibn.fm/ONAR

• York Claims acquisition adds 2.1 km² of strategic mineral rights directly adjacent to existing gold resources, enabling significant pit expansion beyond current property boundaries
• Resource modeling from recent PEA demonstrates gold-silver mineralization extends into newly acquired territory, positioning Lahontan for substantial resource growth
• Transaction structure combining cash, equity, and royalty terms reflects disciplined capital allocation while securing immediate operational advantages

Mining companies pursuing growth face a fundamental choice: expand through exploration risk or consolidating proven ground adjacent to existing resources. While exploration offers discovery potential, strategic land acquisition near established mineralization provides more predictable pathways to resource expansion with lower geological risk.

Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) executed precisely, announcing the acquisition of 27 unpatented lode mineral claims directly south of its York pit at the Santa Fe Mine project. The York Claims acquisition represents textbook district consolidation, securing ground that resource modeling indicates contains extensions of known gold-silver mineralization.

Removing Property Boundary Constraints Enables Pit Optimization

The York Claims transaction addresses a critical limitation that constrained Lahontan’s recent Preliminary Economic Assessment: property boundaries that artificially restricted pit shell optimization. Resource modeling completed during the PEA demonstrated that gold-silver mineralization extended beyond Lahontan’s property limits, creating a scenario where economic ore remained inaccessible due to land ownership rather than geological constraints.

“The newly acquired claims will allow a considerable layback of the York pit during mine planning and in mineral resource estimation,” noted CEO Kimberly Ann. “With the addition of the York Claims, that pit can be greatly expanded, potentially adding resource ounces plus opening up compelling targets for further gold and silver mineral resource expansion.”

The acquisition eliminates these artificial constraints, enabling pit designers to follow mineralization patterns rather than property lines. This optimization can result in improved strip ratios, enhanced ore recovery, and extended mine life compared to boundary-constrained operations.

Transaction Structure Balances Growth with Capital Discipline

Lahontan structured the York Claims acquisition through a combination of immediate payments, deferred obligations, and long-term royalty arrangements that demonstrate thoughtful capital allocation. The $10,000 term sheet payment and subsequent $50,000 promissory note with 2 million shares provide Emergent Metals with immediate consideration while preserving Lahontan’s cash resources for development activities.

The 1% Net Smelter Return royalty creates ongoing value sharing while providing Lahontan with buyback options at $500,000 within three years or $1,000,000 between years three and seven. This structure reflects the realities of junior mining finance, where cash conservation remains paramount while securing strategic assets.

Resource Expansion Potential Enhances Development Economics

Beyond removing pit design constraints, the York Claims acquisition opens additional exploration targets that could substantially increase Lahontan’s 2-million-ounce Santa Fe resource base. Resource expansion carries particular importance for heap leach operations like Santa Fe, where economies of scale directly impact operating costs and project returns.

The Walker Lane district’s geological characteristics support this expansion potential, with mineralization typically occurring in connected systems rather than isolated deposits. Lahontan’s systematic approach to consolidating surrounding claims positions the company to capitalize on these geological relationships.

Regional Context Supports Strategic Timing

The York Claims acquisition occurs within Nevada’s broader consolidation trend, as companies recognize the value of controlling contiguous land packages in proven districts. The timing proves advantageous as gold prices remain elevated and domestic production gains strategic importance under current policies.

The acquisition integrates seamlessly with Lahontan’s existing development timeline, as permitting activities continue progressing toward the targeted early 2027 production start. The expanded property position strengthens permit applications by demonstrating comprehensive resource control and long-term development potential.

CEO Kimberly Ann’s experience navigating complex transactions positions Lahontan to execute both the land acquisition integration and broader development strategy effectively. The consolidation of strategic ground adjacent to established resources represents fundamental mining industry best practices, removing artificial constraints while creating pathways for organic growth.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF

• ESGold continues to build toward the commencement of tailings cleanup at a legacy Quebec mining site during the next few months, aiming to provide environmental recovery at the site while recovering precious metals still in the piles
• ESGold also announced this month that it has signed a joint venture development agreement for similar recovery with a company operating at historic mine site in Colombia
• The company has developed its tailings-to-cash-flow model as an innovative and scalable way to generate returns for shareholders without continual dilution through capital raises
• The region in Colombia is regarded as one of South America’s most prolific gold-producing regions and ESGold is anticipating the agreement will prove to be a launchpad for proving it can scale its model across multiple international jurisdictions

Clean process gold and silver recovery company ESGold (CSE: ESAU) (OTCQB: ESAUF) is announcing a joint venture (”JV”) development that expands the company’s operations beyond eastern Canada and into one of South America’s most prolific gold-producing regions.

ESGold has been building toward the start of production at its fully permitted holdings in Quebec, where it intends to establish the clean recovery of tailings left over from another company’s operations — effectively extracting precious metals.

The company announced Aug. 20 that it has now entered a binding memorandum of understanding with Colombia’s Planta Magdalena S.A.S. (“Planta”) to form the JV with the aim of developing and reprocessing fully permitted, gold- and silver-bearing tailings in that country’s Department of Bolívar.

The announcement exhibits ESGold’s potential for scalable production while delivering environmental remediation benefits to historic mining sites. ESGold’s low-capex, high-margin tailings model developed at the Montauban property in Quebec is expected to get under way in the next few months, using a mill circuit and related assembly to begin reprocessing the tailings.

“Bolívar has a long and storied history as one of Colombia’s most prolific gold-producing regions, with decades of artisanal and small-scale mining contributing significantly to the country’s overall output,” ESGold CEO Gordon Robb stated in the company’s announcement (https://ibn.fm/9Zu2a).

“The region still processes hundreds of thousands of tonnes of ore annually, yet much of it is handled using rudimentary mercury amalgamation methods that leave behind a substantial amount of gold and silver in the tailings. This creates an immense opportunity for ESGold to apply modern, environmentally responsible recovery technology that can significantly improve yields while remediating legacy mine sites,” he added.

The company’s tailings-to-cash-flow model and near surface hardrock is expected to generate close to $350 million from the recovery operation in Quebec during the next four or five years. That money can then be reinvested in the company’s operations, paving the way for new exploration and discovery at the site (https://ibn.fm/llixr).

Due diligence at the Planta Magdalena site included the collection of 27 tailings samples, eight of which assayed above 5 g/t of gold, including several high-grade results. Several samples also returned notable values exceeding 190 g/t of silver, according to the company.

While additional systematic sampling and metallurgical test work are required to determine grade continuity, recoveries, and economic parameters, the company believes the Bolívar opportunity perfectly fits its vision for ESGold’s growth.

“The initial sample results are encouraging, and we’re eager to complete the next stages of technical and legal due diligence,” Chairman and COO Paul Mastantuono stated. “Our team sees this as a launchpad to scale our proven model across multiple jurisdictions, delivering value for shareholders while making a measurable positive impact in the communities where we operate.”

As ESGold delivers predictable, repeatable cash flow that in turn funds exploration and discovery without relying on continual equity dilution, the company expects to create a balance of stability and growth that allows its value to compound over time.

For more information, visit the company’s website at https://esgold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF